CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report

  • ID: 4413997
  • Company Profile
  • 47 pages
  • MarketLine
1 of 3
CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report

Summary:

CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company.

Key Highlights:

CRISPR Therapeutics AG (CRISPR or "the company") is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. The company classifies its business into single operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing technology. Through its CRISPR/Cas9 gene-editing technology, the company allows selective deletion, modification or correction of a disease causing abnormality in a specific DNA segment. It primarily operates in Switzerland, the UK, and the US. The company is headquartered in Basel, Switzerland.

Scope:
  • Detailed information on CRISPR Therapeutics required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting CRISPR Therapeutics in the form of a SWOT analysis
  • An in-depth view of the business model of CRISPR Therapeutics including a breakdown and examination of key business segments
  • Intelligence on CRISPR Therapeutics's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
  • News about CRISPR Therapeutics, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to Purchase:
  • Gain understanding of CRISPR Therapeutics and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess CRISPR Therapeutics as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on CRISPR Therapeutics's business structure, strategy and prospects.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Company Snapshot
  • CRISPR Therapeutics: Company Overview
  • CRISPR Therapeutics: Overview and Key Facts
  • - CRISPR Therapeutics: Overview
  • - CRISPR Therapeutics: Key Facts
  • CRISPR Therapeutics: Key Employees
  • CRISPR Therapeutics: Key Employee Biographies
  • CRISPR Therapeutics: Major Products and Services
  • CRISPR Therapeutics: Company History
  • CRISPR Therapeutics: Management Statement
  • CRISPR Therapeutics: Key Competitors
CRISPR Therapeutics: Company Analysis
  • CRISPR Therapeutics: Business Description
  • CRISPR Therapeutics: SWOT Analysis
  • - CRISPR Therapeutics: SWOT Overview
  • - CRISPR Therapeutics: Strengths
  • - CRISPR Therapeutics: Weaknesses
  • - CRISPR Therapeutics: Opportunities
  • - CRISPR Therapeutics: Threats
  • CRISPR Therapeutics: Corporate Financial Deals Activity
  • CRISPR Therapeutics: Financial Deals Overview
  • CRISPR Therapeutics: Targets and Partners
  • CRISPR Therapeutics: Top Deals 2013 - 2017YTD*
  • CRISPR Therapeutics: Advisors
  • - CRISPR Therapeutics: Top Legal Advisors
  • - CRISPR Therapeutics: Top Financial Advisors
  • CRISPR Therapeutics: Capital Raising
  • CRISPR Therapeutics: Partnership
  • CRISPR Therapeutics: Private Equity and Ownership
CRISPR Therapeutics: Recent Developments
  • CRISPR Therapeutics: News and Events Summary
  • CRISPR Therapeutics: Business Expansion
  • CRISPR Therapeutics: Corporate Governance
  • CRISPR Therapeutics: Financial Deals
  • CRISPR Therapeutics: Financial Performance
  • CRISPR Therapeutics: Grants
  • CRISPR Therapeutics: Market Developments
  • CRISPR Therapeutics: Regulatory and Legal Events
  • CRISPR Therapeutics: Research & Development
  • CRISPR Therapeutics: Strategy and Operations
Appendix
  • Contact Us
  • Methodology
  • Definitions
  • About the Publisher
List of Tables:
Table 1: CRISPR Therapeutics: Key Facts
Table 2: CRISPR Therapeutics: Key Employees
Table 3: CRISPR Therapeutics: Key Competitors
Table 4: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (TTM*)
Table 5: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (2013 - YTD*2017)
Table 6: CRISPR Therapeutics: Targets and Partners
Table 7: CRISPR Therapeutics: Top Deals 2013 - 2017YTD*
Table 8: CRISPR Therapeutics: Legal Advisor Ranking by Value (US$m)
Table 9: CRISPR Therapeutics: Financial Advisor Ranking by Value (US$m)
Table 10: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2013 - YTD*2017)
Table 11: CRISPR Therapeutics: Capital Raising by Deal Type (2013 - YTD*2017)
Table 12: CRISPR Therapeutics: Partnership Volume and Value Trend (2013 - YTD*2017)
Table 13: CRISPR Therapeutics: Partnership Trend by Deal Type (2013 - YTD*2017)
Table 14: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2013 - YTD*2017)
Table 15: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2013 - YTD*2017)
Table 16: CRISPR Therapeutics: News and Events Summary
Table 17: CRISPR Therapeutics: Business Expansion
Table 18: CRISPR Therapeutics: Corporate Governance
Table 19: CRISPR Therapeutics: Financial Deals
Table 20: CRISPR Therapeutics: Financial Performance
Table 21: CRISPR Therapeutics: Grants
Table 22: CRISPR Therapeutics: Market Developments
Table 23: CRISPR Therapeutics: Regulatory and Legal Events
Table 24: CRISPR Therapeutics: Research & Development
Table 25: CRISPR Therapeutics: Strategy and Operations

List of Figures:
Figure 1: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (2013 - YTD*2017)
Figure 3: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2013 - YTD*2017)
Figure 4: CRISPR Therapeutics: Capital Raising by Deal Type (2013 - YTD*2017)
Figure 5: CRISPR Therapeutics: Partnership Volume and Value Trend (2013 - YTD*2017)
Figure 6: CRISPR Therapeutics: Partnership Trend by Deal Type (2013 - YTD*2017)
Figure 7: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2013 - YTD*2017)
Figure 8: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2013 - YTD*2017)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll